Tampa company Morphogenesis, a UF startup, has received a “fast track” designation for its skin cancer vaccination from the United States Food and Drug Administration.
Morphogenesis is a clinical-stage biotechnology company that specializes in development of cell and gene therapy products to treat diseases such as cancer. It announced that its lead clinical-stage candidate, a drug called IFx-Hu2.0, will be fast tracked by the FDA to treat patients with advanced skin cancer.
Read more about Tampa Company Morphogenesis Receives ‘Fast Track’ Designation From FDA for Skin Cancer Vaccine.
